AbbVie Inc.

ABBV · NYSE · SIC 2834: Pharmaceutical Preparations · Market Cap: $365.6B · 57,000 employees
195
SEC Filings
$215.4
Close 2026-05-27
57,000
Employees

Business Summary

AbbVie Inc. is a global, diversified research-based biopharmaceutical company focused on immunology, neuroscience, oncology, and aesthetics. Key products include Skyrizi (risankizumab) and Rinvoq (upadacitinib) for autoimmune diseases, Humira (adalimumab), Vraylar (cariprazine) for neurological conditions, Imbruvica (ibrutinib) and Venclexta (venetoclax) for blood cancers, and Botox Cosmetic and Botox Therapeutic for aesthetic and therapeutic applications. AbbVie develops, manufactures, and commercializes therapies addressing complex and serious diseases globally.

Latest Stock Quote

ABBV 2026-05-27 $215.4 O:$213.12 H:$215.94 L:$211.36 Vol:4.6M VWAP:$214.9082
origin leaf: 68465fad5d0e49a87fc6c1f334469b1511d2be94189209f3c5362d21057126ac

Next Earnings

Q2 FY2026 — expected 2026-09-14

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-202025-12-310001551152-26-000008EDGAR71K words
2025-02-142024-12-310001551152-25-000020EDGAR—
2024-02-202023-12-310001551152-24-000011EDGAR—
2023-02-172022-12-310001551152-23-000011EDGAR—
2022-02-182021-12-310001551152-22-000007EDGAR—
2021-02-192020-12-310001551152-21-000008EDGAR—
2020-02-212019-12-310001551152-20-000007EDGAR—
2019-02-272018-12-310001551152-19-000008EDGAR—
2018-02-162017-12-310001551152-18-000014EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-05-082026-03-310001551152-26-000017EDGAR18K words
2025-11-042025-09-300001551152-25-000049EDGAR26K words
2025-08-042025-06-300001551152-25-000040EDGAR—
2025-05-092025-03-310001551152-25-000029EDGAR—
2024-11-042024-09-300001551152-24-000040EDGAR—
2024-08-072024-06-300001551152-24-000031EDGAR—
2024-05-032024-03-310001551152-24-000020EDGAR—
2023-11-062023-09-300001551152-23-000045EDGAR—
2023-08-072023-06-300001551152-23-000033EDGAR—
2023-05-052023-03-310001551152-23-000023EDGAR—
2022-11-042022-09-300001551152-22-000045EDGAR—
2022-08-042022-06-300001551152-22-000030EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-05-120001104659-26-059484EDGAR1K words
2026-04-290001551152-26-000013EDGAR5K words
2026-04-030001551152-26-000011EDGAR1K words
2026-03-040001104659-26-023534EDGAR—
2026-02-260001104659-26-020643EDGAR—
2026-02-040001551152-26-000004EDGAR—
2026-01-070001551152-26-000002EDGAR—
2025-10-310001551152-25-000047EDGAR—
2025-10-030001551152-25-000043EDGAR—
2025-09-110001104659-25-089245EDGAR—

195 total filings indexed. 164 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

immunology neuroscience oncology aesthetics rheumatology dermatology gastroenterology hematology

Company Identity

CIK0001551152
TickerABBV
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE
Websitehttps://www.abbvie.com
Listed2012-12-10

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: da5e5577045b5061da01f16cd5150578b9b7961d8988178d492a8799d7d0c9a9
parent: 82c773dc69a28c4cb56b8df298ab70d89a795bd51f3aeafc2ee8e609bbc33550
content hash: 86ad1a7c234f004e5bcca69751bd15c7f9e6ecb00d73f08ad282ea6680fed162
signed: 2026-06-02T19:00:02.377Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf